Barclays’s Annovis Bio ANVS Stock Holding History

Barclays’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,866	Closed	-$3.47K	–	5384
2026 Q2	$3.47K	Buy	+1,866	New	+$3.63K	﹤0.01%	4816
2025 Q2	–	Sell	-2	Closed	-$3	–	5243
2025 Q1	$3	Buy	+2	New	+$6	﹤0.01%	5201

Other funds holding ANVS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sherry Group Mountain Home, Arkansas $107M AUM 11.17% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.25% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $606M AUM 21.78% 1-Year Est. Return

Gill Capital Partners Denver, Colorado $366M AUM 12.21% 1-Year Est. Return

Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return

R Squared Central, Hong Kong $188M AUM 18.2% 1-Year Est. Return

Quadcap Wealth Management Frisco, Texas $1.06B AUM 19.48% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays's ANVS Position: Q3 2026 in Review

Barclays sold out of Annovis Bio (ANVS) in Q3 2026, closing a stake of 1,866 shares — an estimated $3.47K sold.

Barclays first reported a position in ANVS in Q1 2025 and held it in 2 quarters. The position peaked at $3.47K in Q2 2026. 24 funds tracked by Wall St. Rank hold ANVS as of Q3 2026.

Barclays reported no remaining Annovis Bio position as of Q3 2026 after selling out during the quarter.
Barclays sold 1,866 Annovis Bio shares in Q3 2026, an estimated $3.47K.
Barclays first reported a position in Annovis Bio in Q1 2025 and held it in 2 quarters.
Barclays's Annovis Bio position peaked at $3.47K in Q2 2026.
24 funds tracked by Wall St. Rank held Annovis Bio as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.